Compare Stocks: HOWL, CYPH, KRRO, and MOLN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$2.42 +6.6%	$0.94	$0.27 ▼ $3.70	$260.79M	0.33	8.50 million shs	16.90 million shs
HOWL Werewolf Therapeutics	$0.97 +2.4%	$0.51	$0.27 ▼ $2.38	$46.96M	0.51	20.22 million shs	487,278 shs
KRRO Korro Bio	$12.24 +5.3%	$12.67	$5.20 ▼ $55.89	$180.25M	3.09	79,148 shs	78,429 shs
MOLN Molecular Partners	$4.29 -1.5%	$4.12	$3.53 ▼ $5.36	$175.63M	1.09	1,216 shs	2,167 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	0.00%	+41.52%	+259.16%	+366.46%	+734.77%
HOWL Werewolf Therapeutics	0.00%	+2.44%	+139.90%	+146.32%	-29.47%
KRRO Korro Bio	0.00%	-5.19%	+0.99%	+14.18%	-52.98%
MOLN Molecular Partners	0.00%	-4.78%	+4.56%	+9.87%	+15.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$2.42 +6.6%	$0.94	$0.27 ▼ $3.70	$260.79M	0.33	8.50 million shs	16.90 million shs
HOWL Werewolf Therapeutics	$0.97 +2.4%	$0.51	$0.27 ▼ $2.38	$46.96M	0.51	20.22 million shs	487,278 shs
KRRO Korro Bio	$12.24 +5.3%	$12.67	$5.20 ▼ $55.89	$180.25M	3.09	79,148 shs	78,429 shs
MOLN Molecular Partners	$4.29 -1.5%	$4.12	$3.53 ▼ $5.36	$175.63M	1.09	1,216 shs	2,167 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	0.00%	+41.52%	+259.16%	+366.46%	+734.77%
HOWL Werewolf Therapeutics	0.00%	+2.44%	+139.90%	+146.32%	-29.47%
KRRO Korro Bio	0.00%	-5.19%	+0.99%	+14.18%	-52.98%
MOLN Molecular Partners	0.00%	-4.78%	+4.56%	+9.87%	+15.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYPH Cypherpunk Technologies	2.00	Hold	$1.60	-33.88% Downside
HOWL Werewolf Therapeutics	2.14	Hold	$4.00	313.95% Upside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	36.55% Upside
MOLN Molecular Partners	2.25	Hold	$8.38	95.45% Upside

Current Analyst Ratings Breakdown

Latest HOWL, CYPH, KRRO, and MOLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$1.60
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/19/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$0.90 ➝ $1.60
8/17/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	MOLN Molecular Partners	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	KRRO Korro Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	MOLN Molecular Partners	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/3/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/1/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$0.90

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.29 per share	N/A
HOWL Werewolf Therapeutics	$1.88M	24.98	N/A	N/A	$0.34 per share	2.84
KRRO Korro Bio	$6.39M	28.22	N/A	N/A	$7.01 per share	1.75
MOLN Molecular Partners	N/A	N/A	N/A	N/A	$1.83 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYPH Cypherpunk Technologies	$4.82M	$0.56	4.32	N/A	N/A	N/A	-20.76%	-19.48%	N/A
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)
MOLN Molecular Partners	-$74.41M	-$1.71	N/A	N/A	N/A	N/A	-68.36%	-54.82%	10/29/2026 (Estimated)

Latest HOWL, CYPH, KRRO, and MOLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2026	Q2 2026	MOLN Molecular Partners	-$0.45	-$0.44	+$0.01	-$0.43	N/A	N/A
8/12/2026	Q2 2026	CYPH Cypherpunk Technologies	N/A	$0.18	N/A	$0.18	N/A	N/A
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYPH Cypherpunk Technologies	N/A	79.19	79.19
HOWL Werewolf Therapeutics	N/A	2.91	2.91
KRRO Korro Bio	N/A	9.55	9.55
MOLN Molecular Partners	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYPH Cypherpunk Technologies	30.46%
HOWL Werewolf Therapeutics	64.84%
KRRO Korro Bio	13.18%
MOLN Molecular Partners	26.55%

Insider Ownership

Company	Insider Ownership
CYPH Cypherpunk Technologies	3.50%
HOWL Werewolf Therapeutics	23.60%
KRRO Korro Bio	4.80%
MOLN Molecular Partners	5.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYPH Cypherpunk Technologies	40	107.76 million	103.99 million	Optionable
HOWL Werewolf Therapeutics	40	48.60 million	37.13 million	Optionable
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable

HOWL, CYPH, KRRO, and MOLN Headlines

Recent News About These Companies

Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 86.5%

August 26, 2026 | marketbeat.com

Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash Base

August 26, 2026 | theglobeandmail.com

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

August 25, 2026 | globenewswire.com

Molecular Partners (MOLN) to Release Quarterly Earnings on Tuesday

August 18, 2026 | marketbeat.com

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 49.3% in July

August 16, 2026 | marketbeat.com

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

July 15, 2026 | globenewswire.com

LifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)

July 12, 2026 | theglobeandmail.com

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

July 6, 2026 | globenewswire.com

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

July 2, 2026 | globenewswire.com

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

May 30, 2026 | globenewswire.com

Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit

May 26, 2026 | globenewswire.com

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

May 12, 2026 | globenewswire.com

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

May 4, 2026 | globenewswire.com

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

May 1, 2026 | globenewswire.com

Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712

April 19, 2026 | globenewswire.com

Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting

April 14, 2026 | globenewswire.com

Molecular Partners AG Sponsored ADR

April 10, 2026 | edition.cnn.com

Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors

March 23, 2026 | globenewswire.com

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes

March 19, 2026 | globenewswire.com

Molecular Partners to Hold Three Poster Presentations at AACR 2026

March 17, 2026 | globenewswire.com

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

March 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, CYPH, KRRO, and MOLN Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

$2.42 +0.15 (+6.61%)

As of 09/4/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Werewolf Therapeutics NASDAQ:HOWL

$0.97 +0.02 (+2.38%)

As of 09/4/2026 04:00 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Korro Bio NASDAQ:KRRO

$12.24 +0.62 (+5.34%)

As of 09/4/2026 04:00 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Molecular Partners NASDAQ:MOLN

$4.28 -0.07 (-1.49%)

As of 09/4/2026 03:56 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, CYPH, KRRO, and MOLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, CYPH, KRRO, and MOLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, CYPH, KRRO, and MOLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, CYPH, KRRO, and MOLN Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Werewolf Therapeutics NASDAQ:HOWL

Korro Bio NASDAQ:KRRO

Molecular Partners NASDAQ:MOLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, CYPH, KRRO, and MOLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, CYPH, KRRO, and MOLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, CYPH, KRRO, and MOLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, CYPH, KRRO, and MOLN Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Werewolf Therapeutics NASDAQ:HOWL

Korro Bio NASDAQ:KRRO

Molecular Partners NASDAQ:MOLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools